10/20/2026
This is why we have partnered with the MPN Research Foundation since the year 2000 to help fund vital research initiatives.
MPN Research Foundation:
The pace of innovation in myeloproliferative neoplasms (MPNs) continues to accelerate. Over the past several weeks alone, we have seen multiple developments that reflect both the strength of today’s therapeutic pipeline and the growing momentum across the MPN landscape.
Recent developments include:
• Takeda's approval of rusfertide (MIMRYLO™) for polycythemia vera (PV), introducing a first-in-class approach designed to address hematocrit control and reduce phlebotomy burden.
• PharmaEssentia's label expansion of BESREMi® into essential thrombocythemia (ET), bringing the first new FDA-approved therapy for ET in nearly three decades and expanding treatment options for patients living with this chronic blood cancer.
•pharma&'s manufacturing and supply-chain milestone for Pegasys®, helping to support stable and reliable, long-term treatment availability and continuity of care for patients who rely on peginterferon therapy.
• Karyopharm's submission seeking approval of selinexor plus ruxolitinib for myelofibrosis, a development that continues the field's evolving conversation around endpoints, overall survival, and how we define meaningful clinical benefit in MPNs.
These milestones highlight an important reality: MPN research is advancing on many fronts at once, from new approvals and label expansions to manufacturing investments, and emerging discussions this conference season.
For the MPN Research Foundation, these announcements underscore the importance of intentional engagement across the research ecosystem. We are dedicated to our mission to convene all MPN stakeholders; aligning patient needs, scientific opportunity and real-world implementation.
